Nanjing Deheng Pharmaceutical Technology Co. Ltd. and Nanjing Delova Biotech Co. Ltd. have discovered new sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, cough and pruritus.
In multiple sclerosis (MS), an alteration of neuronal metabolism caused by dysfunction of its proteasome, the cellular machinery responsible for recycling proteins, contributes to neurodegeneration in this inflammatory disease. This finding could be explored for the development of drugs that protect neurons from damage in MS and other neurodegenerative disorders.
At the 11th Congress of the European Academy of Neurology, which was held in Helsinki June 21 to June 24, researchers presented new data on using CAR T cells in autoimmune neurological conditions.
Viva Star Biosciences (Suzhou) Co Ltd. and Viva Star Biosciences (US) Inc. have patented new NLRP3 inflammasome inhibitors reported to be useful for the treatment of neurodegeneration, metabolic diseases, inflammatory disorders, cancer and genetic disorders.
Cure Rare Disease has successfully completed a pre-IND meeting with the FDA regarding its investigational gene therapy program for limb-girdle muscular dystrophy type 2I/R9 (LGMDR9).
Heterocyclic compounds acting as potassium channel subfamily T member 1 (KCNT1) and KCNT1 mutant inhibitors have been reported in a Actio Biosciences Inc. patent as potentially useful for the treatment of neurological disorders.
In recognition of the fact that diversity, equity and inclusion (DEI) are necessary prerequisites for precision medicine, the European Academy of Neurology (EAN) announced the launch of a DEI Hub at its 11th Congress, which is being held in Helsinki through June 24. “We know now that when we talk about personalized medicine, we have to understand that talking about stroke, for example, in a woman is different than talking about stroke in a man,” EAN president Elena Moro told the audience at the opening session of the conference.
Actio Biosciences Inc. has synthesized potassium channel subfamily T member 1 (KCNT1) inhibitors reported to be useful for the treatment of Brugada’s syndrome, early infantile epileptic encephalopathy, epilepsy of infancy with migrating focal seizures, epileptic encephalopathy, nocturnal frontal lobe epilepsy, infantile spasm, Lennox-Gastaut syndrome and myocardial infarction, among others.
RSS
